These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1524919)

  • 41. Ten-year outcome after combined modality therapy for inflammatory breast cancer.
    Harris EE; Schultz D; Bertsch H; Fox K; Glick J; Solin LJ
    Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1200-8. PubMed ID: 12654428
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Docetaxel followed by fluorouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer.
    Iwata H; Sato N; Masuda N; Nakamura S; Yamamoto N; Kuroi K; Kurosumi M; Tsuda H; Akiyama F; Ohashi Y; Toi M
    Jpn J Clin Oncol; 2011 Jul; 41(7):867-75. PubMed ID: 21719750
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination chemotherapy of breast cancer.
    Cooper RG
    Mt Sinai J Med; 1985 Jun; 52(6):443-6. PubMed ID: 3875023
    [No Abstract]   [Full Text] [Related]  

  • 44. The use of neoadjuvant CMF to avoid mastectomy.
    George ML; Hale PC; Gumpert JR; Hogbin BM; Deutsch GP; Yelland A
    Eur J Surg Oncol; 1999 Feb; 25(1):50-3. PubMed ID: 10188855
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Immunomodulating effects of indomethacin in breast cancer].
    Polevaia EB; Chikvashvili BSh; Kupin VI; Letiagin VP
    Sov Med; 1987; (8):27-30. PubMed ID: 3423958
    [No Abstract]   [Full Text] [Related]  

  • 47. Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
    Liao Z; Strom EA; Buzdar AU; Singletary SE; Hunt K; Allen PK; McNeese MD
    Int J Radiat Oncol Biol Phys; 2000 Jul; 47(5):1191-200. PubMed ID: 10889372
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Primary chemotherapy in the treatment of inflammatory breast carcinoma: a study of 230 cases from the Institut Gustave-Roussy.
    Rouëssé J; Friedman S; Sarrazin D; Mouriesse H; Le Chevalier T; Arriagada R; Spielmann M; Papacharalambous A; May-Levin F
    J Clin Oncol; 1986 Dec; 4(12):1765-71. PubMed ID: 3783202
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone.
    Pinnamaneni K; Yap HY; Buzdar AU; Distefano A; Blumenschein GR
    Cancer; 1984 May; 53(9):1841-4. PubMed ID: 6546706
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Neoadjuvant chemotherapy before definitive treatment for stage III carcinoma of the breast.
    Schwartz GF; Cantor RI; Biermann WA
    Arch Surg; 1987 Dec; 122(12):1430-4. PubMed ID: 3689121
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G; Di Blasio B; Boni C; Bisagni G; Ceci G; Rondini E; Bella M; Leonardi F; Savoldi L; Camisa R; Bruzzi P
    Cancer; 2002 Jul; 95(2):228-35. PubMed ID: 12124820
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary chemotherapy in breast cancer: correlation between tumor response and patient outcome.
    Ferrière JP; Assier I; Curé H; Charrier S; Kwiatkowski F; Achard JL; Dauplat J; Chollet P
    Am J Clin Oncol; 1998 Apr; 21(2):117-20. PubMed ID: 9537193
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Recurrence rates after DCE-MRI image guided planning for breast-conserving surgery following neoadjuvant chemotherapy for locally advanced breast cancer patients.
    Garimella V; Qutob O; Fox JN; Long ED; Chaturvedi A; Turnbull LW; Drew PJ
    Eur J Surg Oncol; 2007 Mar; 33(2):157-61. PubMed ID: 17085007
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Patterns of failure of complete responders following high-dose chemotherapy and autologous bone marrow transplantation for metastatic breast cancer: implications for the use of adjuvant radiation therapy.
    Mundt AJ; Sibley GS; Williams S; Rubin SJ; Heimann R; Halpern H; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):151-60. PubMed ID: 8083108
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Accelerated superfractionated radiotherapy for inflammatory breast carcinoma: complete response predicts outcome and allows for breast conservation.
    Arthur DW; Schmidt-Ullrich RK; Friedman RB; Wazer DE; Kachnic LA; Amir C; Bear HD; Hackney MH; Smith TJ; Lawrence W
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):289-96. PubMed ID: 10760421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM; Heo DS; Lee KH; Byun JH; Chang HM; Noh DY; Choe KJ; Bang YJ; Kim SR; Kim NK
    Cancer; 2000 Dec; 89(12):2521-6. PubMed ID: 11135211
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group Study.
    Rivkin SE; Green S; Metch B; Glucksberg H; Gad-el-Mawla N; Constanzi JJ; Hoogstraten B; Athens J; Maloney T; Osborne CK
    J Clin Oncol; 1989 Sep; 7(9):1229-38. PubMed ID: 2671283
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The feasibility of minimally invasive surgery for stage IIA, IIB, and IIIA breast carcinoma patients after tumor downstaging with induction chemotherapy.
    Vlastos G; Mirza NQ; Lenert JT; Hunt KK; Ames FC; Feig BW; Ross MI; Buzdar AU; Singletary SE
    Cancer; 2000 Mar; 88(6):1417-24. PubMed ID: 10717625
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Breast conservation after induction chemotherapy for locally advanced breast cancer.
    Kling KM; Ostrzega N; Schmit P
    Am Surg; 1997 Oct; 63(10):861-4. PubMed ID: 9322658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.